At AbbVie, we are committed to tackling the toughest challenges in oncology. Our team of oncology experts is working to transform the way cancer is treated and to develop and deliver breakthroughs for patients.
AbbVie is committed to the study of hematologic diseases, driving innovation in chronic lymphocytic leukemia, acute myeloid leukemia, multiple myeloma and other blood cancers.
AbbVie is leveraging our expertise in blood cancer for novel research
in some of the most difficult-to-treat solid tumors.
International Myeloma Foundation
Charting the role of genetic mutations through real-world evidence
AbbVie and the International Myeloma Foundation (IMF) are
collaborating on a landmark retrospective chart review study to better
understand and manage multiple myeloma (MM), the second-most common
blood cancer.  Results of the study will provide insight into the
relatively unknown role of the t(11;14) translocation genetic mutation
in response to treatment, with the potential to advance care for